Practical Laboratory Medicine最新文献_第5页

Target recycling amplification (TRA) combined with multiple strand displacement amplification (SDA) for sensitive detection of Epstein-Barr virus microRNA. 靶向再循环扩增（TRA）联合多链位移扩增（SDA）灵敏检测eb病毒microRNA。

IF 1.3 Q3 MEDICAL LABORATORY TECHNOLOGY

Practical Laboratory Medicine

Pub Date : 2025-08-06 eCollection Date: 2025-09-01 DOI: 10.1016/j.plabm.2025.e00496

Yuying Ye, Guoqing Wu, Siying Wang, Feng Zhou, Yafei Su, Guiyu Zhou, Yusheng Lu, Hui Wu

Objectives: Epstein-Barr virus (EBV) infection is strongly associated with the development of nasopharyngeal carcinoma. However, existing diagnostic methods based on EBV antibodies and plasma DNA exhibit insufficient sensitivity and specificity for early detection. This study aimed to overcome this limitation by developing a highly sensitive and specific method for detecting the EBV-encoded biomarker microRNA miR-BART6-3p.

Methods: We designed a probe (EB4) containing a C-rich sequence, a restriction endonuclease half-recognition site, a G-rich stem-loop structure, and a target recognition domain. Based on this probe, an isothermal fluorescence platform was developed by integrating target recycling amplification (TRA) with strand displacement amplification (SDA). The detection mechanism relies on miR-BART6-3p initiating a polymerase-endonuclease cycle, which generates G-quadruplex structures and target-like DNA. The fluorescence signal is produced when Thioflavin T (ThT) binds to these G-quadruplexes. The sensitivity, specificity, and anti-interference capability of the method were systematically evaluated.

Results: The assay exhibited a broad linear detection range for miR-BART6-3p, spanning from 1 pM to 100 nM, with an ultra-low detection limit of 0.143 pM, thereby demonstrating significantly enhanced sensitivity compared to conventional methods. The assay also displayed high specificity, effectively differentiating targets with single-base mismatches. Clinical evaluation using serum samples revealed markedly elevated fluorescence signals in EBV-positive patients relative to healthy controls. Furthermore, the platform exhibited strong anti-interference capability, ensuring reliable performance under complex biological conditions.

Conclusions: This study successfully developed a one-step, single-probe method for detecting EBV miRNA (miR-BART6-3p) with high sensitivity and specificity. The TRA-SDA platform provides operational simplicity, high interference resistance, and superior diagnostic performance. This innovative approach shows great clinical application prospects as a molecular diagnostic tool for the early detection of nasopharyngeal carcinoma.

目的：eb病毒（EBV）感染与鼻咽癌的发展密切相关。然而，现有的基于EBV抗体和血浆DNA的诊断方法对早期发现的敏感性和特异性不足。本研究旨在通过开发一种高灵敏度和特异性的方法来检测ebv编码的生物标志物microRNA miR-BART6-3p，从而克服这一限制。方法：我们设计了一个探针（EB4），包含一个富含c的序列、一个限制性内切酶半识别位点、一个富含g的茎环结构和一个目标识别域。基于该探针，将靶循环扩增（TRA）与链位移扩增（SDA）相结合，建立了等温荧光平台。检测机制依赖于miR-BART6-3p启动聚合酶-核酸内切酶循环，产生g -四重体结构和靶样DNA。当硫黄素T （ThT）与这些g -四联体结合时产生荧光信号。系统评价了该方法的灵敏度、特异度和抗干扰能力。结果：该方法对miR-BART6-3p具有较宽的线性检测范围，从1 pM到100 nM，超低检出限为0.143 pM，与传统方法相比，灵敏度显着提高。该检测还显示出高特异性，可以有效地区分单碱基不匹配的靶标。使用血清样本的临床评估显示ebv阳性患者的荧光信号明显高于健康对照组。此外，该平台具有较强的抗干扰能力，确保了在复杂生物条件下的可靠性能。结论：本研究成功建立了一步、单探针检测EBV miRNA （miR-BART6-3p）的方法，具有较高的灵敏度和特异性。TRA-SDA平台提供操作简单，高抗干扰性和卓越的诊断性能。该方法作为鼻咽癌早期诊断的分子诊断工具具有广阔的临床应用前景。

{"title":"Target recycling amplification (TRA) combined with multiple strand displacement amplification (SDA) for sensitive detection of Epstein-Barr virus microRNA.","authors":"Yuying Ye, Guoqing Wu, Siying Wang, Feng Zhou, Yafei Su, Guiyu Zhou, Yusheng Lu, Hui Wu","doi":"10.1016/j.plabm.2025.e00496","DOIUrl":"10.1016/j.plabm.2025.e00496","url":null,"abstract":"<p><strong>Objectives: </strong>Epstein-Barr virus (EBV) infection is strongly associated with the development of nasopharyngeal carcinoma. However, existing diagnostic methods based on EBV antibodies and plasma DNA exhibit insufficient sensitivity and specificity for early detection. This study aimed to overcome this limitation by developing a highly sensitive and specific method for detecting the EBV-encoded biomarker microRNA miR-BART6-3p.</p><p><strong>Methods: </strong>We designed a probe (EB4) containing a C-rich sequence, a restriction endonuclease half-recognition site, a G-rich stem-loop structure, and a target recognition domain. Based on this probe, an isothermal fluorescence platform was developed by integrating target recycling amplification (TRA) with strand displacement amplification (SDA). The detection mechanism relies on miR-BART6-3p initiating a polymerase-endonuclease cycle, which generates G-quadruplex structures and target-like DNA. The fluorescence signal is produced when Thioflavin T (ThT) binds to these G-quadruplexes. The sensitivity, specificity, and anti-interference capability of the method were systematically evaluated.</p><p><strong>Results: </strong>The assay exhibited a broad linear detection range for miR-BART6-3p, spanning from 1 pM to 100 nM, with an ultra-low detection limit of 0.143 pM, thereby demonstrating significantly enhanced sensitivity compared to conventional methods. The assay also displayed high specificity, effectively differentiating targets with single-base mismatches. Clinical evaluation using serum samples revealed markedly elevated fluorescence signals in EBV-positive patients relative to healthy controls. Furthermore, the platform exhibited strong anti-interference capability, ensuring reliable performance under complex biological conditions.</p><p><strong>Conclusions: </strong>This study successfully developed a one-step, single-probe method for detecting EBV miRNA (miR-BART6-3p) with high sensitivity and specificity. The TRA-SDA platform provides operational simplicity, high interference resistance, and superior diagnostic performance. This innovative approach shows great clinical application prospects as a molecular diagnostic tool for the early detection of nasopharyngeal carcinoma.</p>","PeriodicalId":20421,"journal":{"name":"Practical Laboratory Medicine","volume":"46 ","pages":"e00496"},"PeriodicalIF":1.3,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144874851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gene variant analysis in pediatrics with early-onset epilepsy: Identification of novel variants 早发性癫痫患儿的基因变异分析：新变异的鉴定

IF 1.7 Q3 MEDICAL LABORATORY TECHNOLOGY

Practical Laboratory Medicine

Pub Date : 2025-07-01 Epub Date: 2025-03-19 DOI: 10.1016/j.plabm.2025.e00462

Pooyan Alizadeh , Armin Jahangiri Babadi , Nemat Ghadiri , Mostafa Neissi , Masoud Zeinali

Background

Epilepsy encompasses a range of brain disorders, often accompanied by growth delay and cerebral palsy. The identification of gene variants is critical for guiding treatment strategies in patients with epilepsy. This study investigates the genetic variants in patients with early-onset epilepsy (EOE) through whole-exome sequencing (WES).

Materials and methods

DNA was extracted from peripheral blood using a standard salting-out method. Gene variants were identified using WES, and sequencing data were analyzed through a two-step approach.

Results

Among 20 subjects, WES identified two novel variants. The first variant, AP3B2 (NM_001278512.2: c.3190G > A; p. Val1064Ile), was located in exon 27 and exhibited homozygosity in the proband and heterozygosity in the parents. The second variant, PIGB (NM_004855.5: c.1664G > C; p.Ter555Serext∗54), was located in exon 12 and demonstrated a similar inheritance pattern. Notably, the PIGB variant was associated with elevated ALP levels.

Conclusion

This study highlights the value of WES in identifying genetic variants associated with epilepsy, particularly the novel AP3B2 and PIGB variants. By focusing on these impactful findings, the study advances understanding of epilepsy genetics and emphasizes the role of WES in enabling early diagnosis, personalized treatment, and improved management strategies.

癫痫包括一系列脑部疾病，常伴有生长迟缓和脑瘫。基因变异的鉴定对于指导癫痫患者的治疗策略至关重要。本研究通过全外显子组测序（WES）研究早发性癫痫（EOE）患者的遗传变异。材料与方法采用标准盐析法从外周血中提取dna。利用WES鉴定基因变异，并通过两步法分析测序数据。结果在20名受试者中，WES鉴定出2个新的变异。第一种改型AP3B2 (NM_001278512.2: c.3190G >；一个;p. Val1064Ile)，位于第27外显子，在先证者中表现为纯合性，在父母中表现为杂合性。第二种改型PIGB (NM_004855.5: c.1664G >；C;p.Ter555Serext * 54)，位于第12外显子，表现出类似的遗传模式。值得注意的是，PIGB变异与ALP水平升高有关。结论本研究强调了WES在识别癫痫相关遗传变异，特别是新型AP3B2和PIGB变异方面的价值。通过关注这些有影响力的发现，本研究推进了对癫痫遗传学的理解，并强调了WES在早期诊断、个性化治疗和改进管理策略方面的作用。

{"title":"Gene variant analysis in pediatrics with early-onset epilepsy: Identification of novel variants","authors":"Pooyan Alizadeh , Armin Jahangiri Babadi , Nemat Ghadiri , Mostafa Neissi , Masoud Zeinali","doi":"10.1016/j.plabm.2025.e00462","DOIUrl":"10.1016/j.plabm.2025.e00462","url":null,"abstract":"<div><h3>Background</h3><div>Epilepsy encompasses a range of brain disorders, often accompanied by growth delay and cerebral palsy. The identification of gene variants is critical for guiding treatment strategies in patients with epilepsy. This study investigates the genetic variants in patients with early-onset epilepsy (EOE) through whole-exome sequencing (WES).</div></div><div><h3>Materials and methods</h3><div>DNA was extracted from peripheral blood using a standard salting-out method. Gene variants were identified using WES, and sequencing data were analyzed through a two-step approach.</div></div><div><h3>Results</h3><div>Among 20 subjects, WES identified two novel variants. The first variant, <strong>AP3B2</strong> (NM_001278512.2: c.3190G > A; p. Val1064Ile), was located in exon 27 and exhibited homozygosity in the proband and heterozygosity in the parents. The second variant, <strong>PIGB</strong> (NM_004855.5: c.1664G > C; p.Ter555Serext∗54), was located in exon 12 and demonstrated a similar inheritance pattern. Notably, the <strong>PIGB</strong> variant was associated with elevated ALP levels.</div></div><div><h3>Conclusion</h3><div>This study highlights the value of WES in identifying genetic variants associated with epilepsy, particularly the novel AP3B2 and PIGB variants. By focusing on these impactful findings, the study advances understanding of epilepsy genetics and emphasizes the role of WES in enabling early diagnosis, personalized treatment, and improved management strategies.</div></div>","PeriodicalId":20421,"journal":{"name":"Practical Laboratory Medicine","volume":"45 ","pages":"Article e00462"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application and concentration selection of dithiothreitol for correcting false elevation of D-dimer 二硫苏糖醇在纠正d -二聚体假升高中的应用及浓度选择

IF 1.7 Q3 MEDICAL LABORATORY TECHNOLOGY

Practical Laboratory Medicine

Pub Date : 2025-07-01 Epub Date: 2025-03-20 DOI: 10.1016/j.plabm.2025.e00469

Jia-Wei Zeng , Guang-Hao Song , Mao Xia

Background

Immunological methods for D-dimer detection are prone to interference, leading to falsely elevated values. This study evaluates the optimal concentration and corrective efficacy of dithiothreitol (DTT) in addressing false D-dimer elevations.

Methods

Plasma samples from seven patients with falsely elevated D-dimer levels, identified using the Sysmex CS5100 coagulation analyzer, were analyzed. Correction was performed using the Stago STA-R Max analyzer with alternative detection antibodies. Additionally, plasma samples from thirty patients with confirmed D-dimer elevations were treated with varying concentrations of DTT (0.01, 0.05, 0.10, and 0.20 mol/L) and normal saline (NS). The optimal concentration of 0.01 mol/L DTT was identified and applied to the experimental group. The results were compared with those obtained using an alternative immunoassay method.

Results

In the true elevation group, samples treated with 0.01 mol/L DTT showed no significant difference in D-dimer levels compared to the NS control or original results (all P > 0.05). Higher concentrations of DTT significantly lowered D-dimer levels compared to the NS group (all P < 0.05). In the experimental group, 0.01 mol/L DTT treatment and the alternative immunoassay method similarly reduced D-dimer levels, with no significant difference between the two correction methods (P > 0.05).

Conclusion

A 0.01 mol/L DTT solution effectively corrects falsely elevated D-dimer levels without affecting true elevations, yielding results comparable to those achieved by changing the immunoassay method.

d -二聚体检测的免疫学方法容易受到干扰，导致错误的升高值。本研究评估了二硫苏糖醇（DTT）在解决假d -二聚体升高中的最佳浓度和矫正效果。方法采用Sysmex CS5100凝血分析仪对7例d -二聚体水平虚高患者的血浆样本进行分析。校正使用Stago STA-R Max分析仪与替代检测抗体。此外，对30例确诊d -二聚体升高的患者的血浆样本进行不同浓度的DTT（0.01、0.05、0.10和0.20 mol/L）和生理盐水（NS）治疗。确定了0.01 mol/L DTT的最佳浓度，并应用于实验组。将结果与采用另一种免疫测定方法获得的结果进行比较。结果在真抬高组中，0.01 mol/L DTT处理的样品d -二聚体水平与NS对照组或原始结果相比无显著差异(P >；0.05)。与NS组相比，高浓度DTT显著降低d -二聚体水平(P <；0.05)。在实验组中，0.01 mol/L DTT处理与替代免疫分析法相似地降低了d -二聚体水平，两种校正方法之间无显著差异(P >；0.05)。结论0.01 mol/L DTT溶液可有效纠正假升高的d -二聚体水平，而不影响真实升高，其结果与改变免疫测定方法的结果相当。

{"title":"Application and concentration selection of dithiothreitol for correcting false elevation of D-dimer","authors":"Jia-Wei Zeng , Guang-Hao Song , Mao Xia","doi":"10.1016/j.plabm.2025.e00469","DOIUrl":"10.1016/j.plabm.2025.e00469","url":null,"abstract":"<div><h3>Background</h3><div>Immunological methods for D-dimer detection are prone to interference, leading to falsely elevated values. This study evaluates the optimal concentration and corrective efficacy of dithiothreitol (DTT) in addressing false D-dimer elevations.</div></div><div><h3>Methods</h3><div>Plasma samples from seven patients with falsely elevated D-dimer levels, identified using the Sysmex CS5100 coagulation analyzer, were analyzed. Correction was performed using the Stago STA-R Max analyzer with alternative detection antibodies. Additionally, plasma samples from thirty patients with confirmed D-dimer elevations were treated with varying concentrations of DTT (0.01, 0.05, 0.10, and 0.20 mol/L) and normal saline (NS). The optimal concentration of 0.01 mol/L DTT was identified and applied to the experimental group. The results were compared with those obtained using an alternative immunoassay method.</div></div><div><h3>Results</h3><div>In the true elevation group, samples treated with 0.01 mol/L DTT showed no significant difference in D-dimer levels compared to the NS control or original results (all P > 0.05). Higher concentrations of DTT significantly lowered D-dimer levels compared to the NS group (all P < 0.05). In the experimental group, 0.01 mol/L DTT treatment and the alternative immunoassay method similarly reduced D-dimer levels, with no significant difference between the two correction methods (P > 0.05).</div></div><div><h3>Conclusion</h3><div>A 0.01 mol/L DTT solution effectively corrects falsely elevated D-dimer levels without affecting true elevations, yielding results comparable to those achieved by changing the immunoassay method.</div></div>","PeriodicalId":20421,"journal":{"name":"Practical Laboratory Medicine","volume":"45 ","pages":"Article e00469"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143903515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of blood centrifugation on the parameters of thrombin generation assay revisited to look for possible revision of the current guidance 重新审视血液离心对凝血酶生成测定参数的影响，以寻找对当前指南的可能修订

IF 1.7 Q3 MEDICAL LABORATORY TECHNOLOGY

Practical Laboratory Medicine

Pub Date : 2025-07-01 Epub Date: 2025-05-31 DOI: 10.1016/j.plabm.2025.e00478

Erica Scalambrino , Marigrazia Clerici , Flora Peyvandi , Armando Tripodi

Blood centrifugation affects thrombin generation assays (TGA). Current guidance recommends double-centrifugation, which is uncommon in clinical laboratories.

We evaluated the impact of 4 centrifugation speeds on TGA performed with low-triggers (1pM tissue-factor/1.0 μM phospholipids) or high-triggers (5pM tissue-factor/5.0 μM phospholipids). TGA parameters were evaluated in the presence/absence of thrombomodulin.

We included 20 healthy subjects. Centrifugation speeds were: (i)Double-centrifugation: blood at 2,500g(15min) and plasma at 2500(15min) (reference method). (ii)Single-centrifugation at 3,000g(20min). (iii)Single-centrifugation of blood at 3,000g(20min), plasma freezing, then centrifugation of thawed plasma at 10,000g(5min). (iv)Single-centrifugation at 1,700g(10min). Results were also expressed as percentage difference relative to reference centrifugation.

Lag-time was affected when centrifugation speed was relatively slow (1,700g), regardless of low- or high-triggers, presence or absence of thrombomodulin, whereas it was scarcely affected by centrifugation at 3,000g. Peak-thrombin was marginally affected at relatively low-speed (1,700g). ETP was marginally affected at relatively low-speed (1,700g), except when TGA was performed in the presence of thrombomodulin. Peak-thrombin and ETP were not or were poorly affected by centrifugation at 3,000g or 10,000g after thawing, respectively.

In conclusion, slow-centrifugation (1,700g) had a considerable impact on lag-time. This centrifugation speed represents common practice in clinical laboratories and should not be used for TGA, unless controls samples centrifuged at the same speed are used for comparison. Single-centrifugation at 3,000g may be a suitable alternative, which would allow TGA testing without the complex and time-consuming double-centrifugation as recommended by current guidance. We propose that current guidance on plasma preparation for TGA be switched from double-to a more intense single-centrifugation.

血液离心影响凝血酶生成测定（TGA）。目前的指导建议双重离心，这在临床实验室中并不常见。我们评估了4种离心速度对低触发（1pM组织因子/1.0 μM磷脂）或高触发（5pM组织因子/5.0 μM磷脂）进行TGA的影响。在存在/不存在血栓调节素的情况下评估TGA参数。我们纳入了20名健康受试者。离心速度：(i)双离心：血液2500g (15min)，血浆2500g (15min)（参考方法）。（ii） 3000g单次离心（20min）。（iii） 3000g血液单次离心（20min），血浆冷冻，再10000g解冻血浆离心（5min）。（iv） 1700 g单次离心（10min）。结果也表示为相对于参考离心的百分比差异。当离心速度相对较慢（1,700g）时，滞后时间受到影响，无论低触发还是高触发，存在或不存在血栓调节素，而在3,000g时，它几乎不受影响。峰值凝血酶在相对低速（1,700g）时受到轻微影响。在相对低速（1,700g）时，ETP受到轻微影响，除非在血栓调节素存在的情况下进行TGA。解冻后分别在3000g和10000g离心对凝血酶峰和ETP没有或影响很小。总之，慢速离心（1,700g）对滞后时间有相当大的影响。此离心速度代表临床实验室的常用做法，不应用于TGA，除非以相同速度离心的对照样品用于比较。3000g的单离心可能是一个合适的选择，这将允许TGA测试，而不需要当前指导建议的复杂和耗时的双离心。我们建议将目前TGA血浆制备的指导从双离心改为更强的单离心。

{"title":"Impact of blood centrifugation on the parameters of thrombin generation assay revisited to look for possible revision of the current guidance","authors":"Erica Scalambrino , Marigrazia Clerici , Flora Peyvandi , Armando Tripodi","doi":"10.1016/j.plabm.2025.e00478","DOIUrl":"10.1016/j.plabm.2025.e00478","url":null,"abstract":"<div><div>Blood centrifugation affects thrombin generation assays (TGA). Current guidance recommends double-centrifugation, which is uncommon in clinical laboratories.</div><div>We evaluated the impact of 4 centrifugation speeds on TGA performed with low-triggers (1pM tissue-factor/1.0 μM phospholipids) or high-triggers (5pM tissue-factor/5.0 μM phospholipids). TGA parameters were evaluated in the presence/absence of thrombomodulin.</div><div>We included 20 healthy subjects. Centrifugation speeds were: (i)Double-centrifugation: blood at 2,500g(15min) and plasma at 2500(15min) (reference method). (ii)Single-centrifugation at 3,000g(20min). (iii)Single-centrifugation of blood at 3,000g(20min), plasma freezing, then centrifugation of thawed plasma at 10,000g(5min). (iv)Single-centrifugation at 1,700g(10min). Results were also expressed as percentage difference relative to reference centrifugation.</div><div>Lag-time was affected when centrifugation speed was relatively slow (1,700g), regardless of low- or high-triggers, presence or absence of thrombomodulin, whereas it was scarcely affected by centrifugation at 3,000g. Peak-thrombin was marginally affected at relatively low-speed (1,700g). ETP was marginally affected at relatively low-speed (1,700g), except when TGA was performed in the presence of thrombomodulin. Peak-thrombin and ETP were not or were poorly affected by centrifugation at 3,000g or 10,000g after thawing, respectively.</div><div>In conclusion, slow-centrifugation (1,700g) had a considerable impact on lag-time. This centrifugation speed represents common practice in clinical laboratories and should not be used for TGA, unless controls samples centrifuged at the same speed are used for comparison. Single-centrifugation at 3,000g may be a suitable alternative, which would allow TGA testing without the complex and time-consuming double-centrifugation as recommended by current guidance. We propose that current guidance on plasma preparation for TGA be switched from double-to a more intense single-centrifugation.</div></div>","PeriodicalId":20421,"journal":{"name":"Practical Laboratory Medicine","volume":"45 ","pages":"Article e00478"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144196456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients 评估越南非小细胞肺癌患者的突变-临床相关性和治疗结果

IF 1.7 Q3 MEDICAL LABORATORY TECHNOLOGY

Practical Laboratory Medicine

Pub Date : 2025-07-01 Epub Date: 2025-05-23 DOI: 10.1016/j.plabm.2025.e00477

Hoang-Bac Nguyen , Bang-Suong Nguyen-Thi , Huu-Huy Nguyen , Minh-Khoi Le , Quoc-Trung Lam , Tuan-Anh Nguyen

Introduction

This study examines the genetic and clinical profiles of Vietnamese patients with non-small cell lung cancer (NSCLC), focusing on mutations in seven driver genes: EGFR, KRAS, NRAS, BRAF, ALK, ROS1, and PIK3CA. The goal is to identify mutation patterns and their correlations with clinical factors, thereby informing personalized treatment strategies.

Materials and methods

A cross-sectional study of 299 NSCLC patients at the University Medical Center, Ho Chi Minh City (2019–2022) recorded demographics, smoking history, and tumor stage. Pre-treatment samples were analyzed via massively parallel sequencing, and survival analysis assessed the impact of EGFR/KRAS mutations on survival and TKI response.

Results

Most patients (88.6 %) were diagnosed at stage IV. EGFR mutations were found in 43.5 % of cases, predominantly in female non-smokers, while KRAS mutations (15.4 %) were more common in male smokers. EGFR exon 19 deletions (46.3 %) and L858R (39.0 %) were the most frequent, with KRAS G12C (29.8 %) as the dominant variant. EGFR-mutant patients treated with TKIs had significantly longer survival (p = 0.027); however, no survival difference was observed between the EGFR- and KRAS-mutated groups. Co-mutations (3.7 %) were rare but may indicate resistance. Logistic regression confirmed EGFR mutations' association with female non-smokers and KRAS mutations with male smokers.

Conclusions

Genetic profiling in Vietnamese NSCLC patients reveals a high prevalence of actionable driver mutations, supporting the integration of routine molecular testing into NSCLC management. EGFR-mutated patients derive significant benefits from TKI therapy, underscoring the importance of personalized treatment strategies. Further research is needed to investigate resistance mechanisms and refine targeted therapeutic approaches.

本研究研究了越南非小细胞肺癌（NSCLC）患者的遗传和临床特征，重点研究了7个驱动基因的突变：EGFR、KRAS、NRAS、BRAF、ALK、ROS1和PIK3CA。目标是确定突变模式及其与临床因素的相关性，从而为个性化治疗策略提供信息。材料和方法对2019-2022年胡志明市大学医学中心299例非小细胞肺癌患者进行了横断面研究，记录了人口统计学、吸烟史和肿瘤分期。预处理样本通过大规模平行测序进行分析，生存分析评估EGFR/KRAS突变对生存和TKI反应的影响。结果大多数患者（88.6%）诊断为IV期，其中EGFR突变发生率为43.5%，以女性非吸烟者为主，而KRAS突变发生率为15.4%，以男性吸烟者为主。EGFR外显子19缺失（46.3%）和L858R缺失（39.0%）最为常见，KRAS G12C缺失（29.8%）为显性变异。接受TKIs治疗的egfr突变患者的生存期明显延长（p = 0.027）；然而，在EGFR-和kras突变组之间没有观察到生存差异。共突变（3.7%）罕见，但可能表明耐药性。Logistic回归证实EGFR突变与女性非吸烟者相关，KRAS突变与男性吸烟者相关。结论越南非小细胞肺癌患者的基因分析显示，可操作的驱动突变非常普遍，支持将常规分子检测整合到非小细胞肺癌的管理中。egfr突变患者从TKI治疗中获益显著，强调了个性化治疗策略的重要性。需要进一步研究耐药机制和改进靶向治疗方法。

{"title":"Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients","authors":"Hoang-Bac Nguyen , Bang-Suong Nguyen-Thi , Huu-Huy Nguyen , Minh-Khoi Le , Quoc-Trung Lam , Tuan-Anh Nguyen","doi":"10.1016/j.plabm.2025.e00477","DOIUrl":"10.1016/j.plabm.2025.e00477","url":null,"abstract":"<div><h3>Introduction</h3><div>This study examines the genetic and clinical profiles of Vietnamese patients with non-small cell lung cancer (NSCLC), focusing on mutations in seven driver genes: <em>EGFR</em>, <em>KRAS</em>, <em>NRAS</em>, <em>BRAF</em>, <em>ALK</em>, <em>ROS1</em>, and <em>PIK3CA</em>. The goal is to identify mutation patterns and their correlations with clinical factors, thereby informing personalized treatment strategies.</div></div><div><h3>Materials and methods</h3><div>A cross-sectional study of 299 NSCLC patients at the University Medical Center, Ho Chi Minh City (2019–2022) recorded demographics, smoking history, and tumor stage. Pre-treatment samples were analyzed via massively parallel sequencing, and survival analysis assessed the impact of <em>EGFR/KRAS</em> mutations on survival and TKI response.</div></div><div><h3>Results</h3><div>Most patients (88.6 %) were diagnosed at stage IV. <em>EGFR</em> mutations were found in 43.5 % of cases, predominantly in female non-smokers, while <em>KRAS</em> mutations (15.4 %) were more common in male smokers. <em>EGFR</em> exon 19 deletions (46.3 %) and L858R (39.0 %) were the most frequent, with <em>KRAS</em> G12C (29.8 %) as the dominant variant. <em>EGFR</em>-mutant patients treated with TKIs had significantly longer survival (p = 0.027); however, no survival difference was observed between the <em>EGFR</em>- and <em>KRAS</em>-mutated groups. Co-mutations (3.7 %) were rare but may indicate resistance. Logistic regression confirmed <em>EGFR</em> mutations' association with female non-smokers and <em>KRAS</em> mutations with male smokers.</div></div><div><h3>Conclusions</h3><div>Genetic profiling in Vietnamese NSCLC patients reveals a high prevalence of actionable driver mutations, supporting the integration of routine molecular testing into NSCLC management. <em>EGFR</em>-mutated patients derive significant benefits from TKI therapy, underscoring the importance of personalized treatment strategies. Further research is needed to investigate resistance mechanisms and refine targeted therapeutic approaches.</div></div>","PeriodicalId":20421,"journal":{"name":"Practical Laboratory Medicine","volume":"45 ","pages":"Article e00477"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-IH in myelodysplastic syndrome 骨髓增生异常综合征的抗ih

IF 1.7 Q3 MEDICAL LABORATORY TECHNOLOGY

Practical Laboratory Medicine

Pub Date : 2025-07-01 Epub Date: 2025-03-22 DOI: 10.1016/j.plabm.2025.e00468

Ketsaraporn Wongba , Pornlada Nuchnoi , Chotiros Plabplueng , Charuporn Promwong

Background

Anti-IH exhibits complex specificity, strongly reacting with cells expressing both H and I antigens at cold temperatures. Its clinical significance has been increasingly recognized, particularly in patients with hematologic conditions such as myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).

Case report

We present an 83-year-old Thai female with MDS who was transfusion-dependent. She presented with severe anemia requiring an urgent transfusion. The patient was group A RhD-positive. Antibody screening and identification using column agglutination technology (CAT) showed weak polyagglutination. Auto-control and direct antiglobulin tests (DAT) were negative. Red cell typing showed absence of H antigen and presence of A1 antigen. Further testing with cord O cells revealed no agglutination, confirming the A1 blood group with anti-IH. Antibody screening and identification studies showed cold-reactivity, with weak reactivity at 37 °C and in the AHG phase. Crossmatching with two group A leukocyte-poor red cells was compatible, and transfusion was uneventful.

Conclusion

This is the first reported case of anti-IH in a Thai patient. Anti-IH may complicate pre-transfusion testing and mask alloantibodies, necessitating careful interpretation and confirmatory testing to prevent transfusion-related complications.

抗ih具有复杂的特异性，在低温下与表达H和I抗原的细胞发生强烈反应。其临床意义已被越来越多地认识到，特别是在血液病患者，如骨髓增生异常综合征（MDS）和慢性髓细胞白血病（CMML）。病例报告：我们报告一位83岁的泰国女性MDS患者，她依赖输血。她表现出严重贫血需要紧急输血。患者为A组rhd阳性。利用柱凝集技术（CAT）进行抗体筛选和鉴定，结果显示抗体存在弱的多凝集现象。自动控制和直接抗球蛋白试验（DAT）均为阴性。红细胞分型显示H抗原缺失，A1抗原存在。脐带O细胞进一步检测未发现凝集，证实A1血型具有抗ih。抗体筛选和鉴定研究显示冷反应性，在37°C和AHG期具有弱反应性。与两个A组白细胞缺乏的红细胞交叉配型是相容的，输血是平稳的。结论这是泰国首次报道的抗ih病例。抗ih可能使输血前检测和屏蔽同种异体抗体复杂化，需要仔细解释和确认性检测，以防止输血相关并发症。

{"title":"Anti-IH in myelodysplastic syndrome","authors":"Ketsaraporn Wongba , Pornlada Nuchnoi , Chotiros Plabplueng , Charuporn Promwong","doi":"10.1016/j.plabm.2025.e00468","DOIUrl":"10.1016/j.plabm.2025.e00468","url":null,"abstract":"<div><h3>Background</h3><div>Anti-IH exhibits complex specificity, strongly reacting with cells expressing both H and I antigens at cold temperatures. Its clinical significance has been increasingly recognized, particularly in patients with hematologic conditions such as myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).</div></div><div><h3>Case report</h3><div>We present an 83-year-old Thai female with MDS who was transfusion-dependent. She presented with severe anemia requiring an urgent transfusion. The patient was group A RhD-positive. Antibody screening and identification using column agglutination technology (CAT) showed weak polyagglutination. Auto-control and direct antiglobulin tests (DAT) were negative. Red cell typing showed absence of H antigen and presence of A1 antigen. Further testing with cord O cells revealed no agglutination, confirming the A1 blood group with anti-IH. Antibody screening and identification studies showed cold-reactivity, with weak reactivity at 37 °C and in the AHG phase. Crossmatching with two group A leukocyte-poor red cells was compatible, and transfusion was uneventful.</div></div><div><h3>Conclusion</h3><div>This is the first reported case of anti-IH in a Thai patient. Anti-IH may complicate pre-transfusion testing and mask alloantibodies, necessitating careful interpretation and confirmatory testing to prevent transfusion-related complications.</div></div>","PeriodicalId":20421,"journal":{"name":"Practical Laboratory Medicine","volume":"45 ","pages":"Article e00468"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143783210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

1,25-dihydroxyvitamin D in the elderly population: Comparison of liquid chromatography tandem mass spectrometry and CLIA immunoassay (LIAISON®XL) methods 老年人群中的1,25-二羟基维生素D：液相色谱串联质谱法和CLIA免疫分析法（LIAISON®XL）方法的比较

IF 1.7 Q3 MEDICAL LABORATORY TECHNOLOGY

Practical Laboratory Medicine

Pub Date : 2025-07-01 Epub Date: 2025-05-08 DOI: 10.1016/j.plabm.2025.e00474

Dorota Leszczyńska , Alicja Szatko , Magdalena Ostrowska , Magdalena Zgliczyńska , Konrad Kowalski , Wojciech Zgliczyński , Piotr Glinicki

Background

1α,25-dihydroxyvitamin D is the biologically active form of vitamin D₃ (cholecalciferol) and vitamin D₂ (ergocalciferol). The determination of 1,25(OH)₂D is clinically relevant in the diagnostics of vitamin D metabolism disorders, PTH-independent hypercalceamia and hypophosphatemic syndromes. The quantitative assessment of 1,25(OH)₂D may be a challenge since it circulates in picomolar concentrations in the blood.

Aims of the study

Comparison of two methods: chemiluminescent immunoassay (CLIA, LIAISON®XL) and Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) for determinations of 1,25(OH)₂D concentrations in elderly populations. The secondary aim was to assess correlation between 1,25(OH)₂D for CLIA_LIAISON®XL and LC-MS/MS methods and selected factors (vitamin D metabolites, calcium, albumin, PTH, creatinine concentrations in serum and age).

Materials and methods

The study was conducted on 54 patients aged from 60 to 96 at the Bielański Hospital in Warsaw, Poland. The determination of 1,25(OH)₂D using CLIA_LIAISON®XL and LC-MS/MS methods was performed.

Results

Both methods (CLIA_LIAISON®XL immunoassay and LC-MS/MS technique) were strongly positively correlated (r = 0.86; p < 0.001). In the LC-MS/MS technique, concentration of 1,25(OH)₂D was significantly higher compared to the CLIA_LIAISON®XL immunoassay. The regression equation revealed method interchangeability. Concentration of 1,25(OH)₂D was significantly correlated with various basic biochemical parameters (albumin and calcium levels) for both methods.

Conclusions

In our study, measurement of 1,25(OH)₂D using CLIA_LIAISON®XL was not inferior to LC-MS/MS measurement. The assessment of 1,25(OH)₂D using CLIA_LIAISON®XL, characterized by short turnaround time, low costs and high accuracy, may be an optimal choice for elderly patients who often require prompt diagnosis and treatment.

α，25-二羟基维生素D是维生素D3（胆钙化醇）和维生素D2（麦角钙化醇）的生物活性形式。1,25(OH)2D的测定在诊断维生素D代谢紊乱、甲状旁腺素非依赖性高钙血症和低磷血症综合征方面具有临床意义。125 (OH)2D的定量评估可能是一个挑战，因为它在血液中以皮摩尔浓度循环。研究目的比较化学发光免疫分析法（CLIA, LIAISON®XL）和液相色谱串联质谱法（LC-MS/MS）测定老年人体内1,25(OH)2D浓度的方法。第二个目的是评估CLIALIAISON®XL和LC-MS/MS方法中1,25(OH)2D与选定因素（维生素D代谢物、钙、白蛋白、甲状旁腺激素、血清肌酐浓度和年龄）之间的相关性。材料与方法该研究在波兰华沙Bielański医院对54名年龄从60岁到96岁的患者进行了研究。采用CLIALIAISON®XL和LC-MS/MS法测定1,25(OH)2D。结果CLIALIAISON®XL免疫分析法与LC-MS/MS技术呈正相关(r = 0.86；p & lt;0.001)。在LC-MS/MS技术中，与CLIALIAISON®XL免疫分析法相比，125 (OH)2D的浓度显著升高。回归方程显示了方法的互换性。两种方法的1,25(OH)2D浓度与各种基本生化参数（白蛋白和钙水平）均显著相关。结论在我们的研究中，CLIALIAISON®XL测量1,25(OH)2D的效果不逊于LC-MS/MS。CLIALIAISON®XL检测1,25(OH)2D具有周转时间短、成本低、准确性高的特点，可能是需要及时诊断和治疗的老年患者的最佳选择。

{"title":"1,25-dihydroxyvitamin D in the elderly population: Comparison of liquid chromatography tandem mass spectrometry and CLIA immunoassay (LIAISON®XL) methods","authors":"Dorota Leszczyńska , Alicja Szatko , Magdalena Ostrowska , Magdalena Zgliczyńska , Konrad Kowalski , Wojciech Zgliczyński , Piotr Glinicki","doi":"10.1016/j.plabm.2025.e00474","DOIUrl":"10.1016/j.plabm.2025.e00474","url":null,"abstract":"<div><h3>Background</h3><div>1α,25-dihydroxyvitamin D is the biologically active form of vitamin D<sub>3</sub> (cholecalciferol) and vitamin D<sub>2</sub> (ergocalciferol). The determination of 1,25(OH)<sub>2</sub>D is clinically relevant in the diagnostics of vitamin D metabolism disorders, PTH-independent hypercalceamia and hypophosphatemic syndromes. The quantitative assessment of 1,25(OH)<sub>2</sub>D may be a challenge since it circulates in picomolar concentrations in the blood.</div></div><div><h3>Aims of the study</h3><div>Comparison of two methods: chemiluminescent immunoassay (CLIA, LIAISON®XL) and Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) for determinations of 1,25(OH)<sub>2</sub>D concentrations in elderly populations. The secondary aim was to assess correlation between 1,25(OH)<sub>2</sub>D for CLIA<sub>LIAISON®XL</sub> and LC-MS/MS methods and selected factors (vitamin D metabolites, calcium, albumin, PTH, creatinine concentrations in serum and age).</div></div><div><h3>Materials and methods</h3><div>The study was conducted on 54 patients aged from 60 to 96 at the Bielański Hospital in Warsaw, Poland. The determination of 1,25(OH)<sub>2</sub>D using CLIA<sub>LIAISON®XL</sub> and LC-MS/MS methods was performed.</div></div><div><h3>Results</h3><div>Both methods (CLIA<sub>LIAISON®XL</sub> immunoassay and LC-MS/MS technique) were strongly positively correlated (r = 0.86; p < 0.001). In the LC-MS/MS technique, concentration of 1,25(OH)<sub>2</sub>D was significantly higher compared to the CLIA<sub>LIAISON®XL</sub> immunoassay. The regression equation revealed method interchangeability. Concentration of 1,25(OH)<sub>2</sub>D was significantly correlated with various basic biochemical parameters (albumin and calcium levels) for both methods.</div></div><div><h3>Conclusions</h3><div>In our study, measurement of 1,25(OH)<sub>2</sub>D using CLIA<sub>LIAISON®XL</sub> was not inferior to LC-MS/MS measurement. The assessment of 1,25(OH)<sub>2</sub>D using CLIA<sub>LIAISON®XL</sub>, characterized by short turnaround time, low costs and high accuracy, may be an optimal choice for elderly patients who often require prompt diagnosis and treatment.</div></div>","PeriodicalId":20421,"journal":{"name":"Practical Laboratory Medicine","volume":"45 ","pages":"Article e00474"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144147095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution of reference intervals for renal-hepatic biomarkers and micronutrients in normal pregnancy during Covid-19 pandemic (2021–2022) in some hospitals of Kinshasa, Democratic Republic of the Congo 刚果民主共和国金沙萨部分医院2019冠状病毒病大流行期间（2021-2022年）正常妊娠期间肝肾生物标志物和微量营养素参考区间的演变

IF 1.7 Q3 MEDICAL LABORATORY TECHNOLOGY

Practical Laboratory Medicine

Pub Date : 2025-07-01 Epub Date: 2025-03-21 DOI: 10.1016/j.plabm.2025.e00466

Eddy Bakemo , Benjamin Longo- Mbenza , Bienvenue Kuyangisa , Dophie Beya , Gédéon Bongo , Mireille Nganga

Background

The aim of this study was to establish the reference intervals of renal, hepatic and micronutrient biomarkers in the course of normal pregnancy.

Methods

This was a descriptive, cross-sectional, exploratory study of the occurrence of biochemical changes in reference intervals during the course of normal pregnancy between June 15, 2021 and March 30, 2022. A total of 473 pregnant women were recruited from 16 hospitals in Kinshasa. Reference intervals at 2.5 and 97.5 percentiles were established according to the recommendations of the International Federation of Clinical Chemistry. The statistical significance was set at p < 0.05. Ethical consideration was obtained from the Comité National d'Ethique en Santé and received approval under number 362/CNES/BN/PMMF/2022.

Results

Mean age was 29 ± 6 years. Reference intervals (RIs) for urea, creatinine, uric acid albumin, phosphorus, calcium and magnesium; alkaline phosphatase, GGT, ALAT and ASAT were 5.4–24.7 mg/dL; 0.39–1.11 mg/dL; 2–6.4 mg/dL; 40.9–53.05 mg/dL; 2. 2–5.9 mg/dL; 6.8–11.6 mg/dL; and 1.3–3.6 mg/dL; 39–246 IU/L; 3–43IU/L; 3.78–26.19 IU/L; 7.8–35.3 IU/L.

Conclusion

The established reference intervals (RIs) will be used to manage pregnancies of pregnant women in Kinshasa.

本研究的目的是建立正常妊娠过程中肾脏、肝脏和微量营养素生物标志物的参考区间。方法对2021年6月15日至2022年3月30日正常妊娠期间参考区间生化变化的发生情况进行描述性、横断面性、探索性研究。从金沙萨的16家医院共招募了473名孕妇。参考区间为2.5和97.5百分位，是根据国际临床化学联合会的建议建立的。统计学意义设为p <；0.05. 伦理考虑已获得法国国家伦理委员会（comit National d’ethque en sant）的批准，并获得第362/CNES/BN/PMMF/2022号批准。结果患者平均年龄29±6岁。尿素、肌酐、尿酸白蛋白、磷、钙和镁的参考区间（RIs）；碱性磷酸酶、GGT、ALAT、ASAT为5.4 ~ 24.7 mg/dL；0.39 - -1.11毫克/分升;2 - 6.4 mg / dL;40.9 - -53.05毫克/分升;2. 2 - 5.9 mg / dL;6.8 - -11.6毫克/分升;1.3 ~ 3.6 mg/dL；39 - 246 IU / L;3-43IU / L;3.78 - -26.19 IU / L;7.8 - -35.3 IU / L。结论建立的参考区间（RIs）可用于金沙萨孕妇妊娠管理。

{"title":"Evolution of reference intervals for renal-hepatic biomarkers and micronutrients in normal pregnancy during Covid-19 pandemic (2021–2022) in some hospitals of Kinshasa, Democratic Republic of the Congo","authors":"Eddy Bakemo , Benjamin Longo- Mbenza , Bienvenue Kuyangisa , Dophie Beya , Gédéon Bongo , Mireille Nganga","doi":"10.1016/j.plabm.2025.e00466","DOIUrl":"10.1016/j.plabm.2025.e00466","url":null,"abstract":"<div><h3>Background</h3><div>The aim of this study was to establish the reference intervals of renal, hepatic and micronutrient biomarkers in the course of normal pregnancy.</div></div><div><h3>Methods</h3><div>This was a descriptive, cross-sectional, exploratory study of the occurrence of biochemical changes in reference intervals during the course of normal pregnancy between June 15, 2021 and March 30, 2022. A total of 473 pregnant women were recruited from 16 hospitals in Kinshasa. Reference intervals at 2.5 and 97.5 percentiles were established according to the recommendations of the International Federation of Clinical Chemistry. The statistical significance was set at p < 0.05. Ethical consideration was obtained from the Comité National d'Ethique en Santé and received approval under number 362/CNES/BN/PMMF/2022.</div></div><div><h3>Results</h3><div>Mean age was 29 ± 6 years. Reference intervals (RIs) for urea, creatinine, uric acid albumin, phosphorus, calcium and magnesium; alkaline phosphatase, GGT, ALAT and ASAT were 5.4–24.7 mg/dL; 0.39–1.11 mg/dL; 2–6.4 mg/dL; 40.9–53.05 mg/dL; 2. 2–5.9 mg/dL; 6.8–11.6 mg/dL; and 1.3–3.6 mg/dL; 39–246 IU/L; 3–43IU/L; 3.78–26.19 IU/L; 7.8–35.3 IU/L.</div></div><div><h3>Conclusion</h3><div>The established reference intervals (RIs) will be used to manage pregnancies of pregnant women in Kinshasa.</div></div>","PeriodicalId":20421,"journal":{"name":"Practical Laboratory Medicine","volume":"45 ","pages":"Article e00466"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrative analysis of exosomal ncRNAs and their regulatory networks in liver cancer progression 肝癌进展中外泌体ncrna及其调控网络的综合分析

IF 1.7 Q3 MEDICAL LABORATORY TECHNOLOGY

Practical Laboratory Medicine

Pub Date : 2025-07-01 Epub Date: 2025-03-21 DOI: 10.1016/j.plabm.2025.e00464

Farzin Mirzaei-nasab , Ahmad Majd , Yousef Seyedena , Nazanin Hosseinkhan , Najma Farahani , Mehrdad Hashemi

Background

Hepatocellular carcinoma (HCC) is a significant global health challenge with complex molecular underpinnings. Recent advancements in understanding the role of non-coding RNAs (ncRNAs) and exosomes in cancer biology have opened new avenues for research into potential diagnostic and therapeutic strategies.

Methods

This study utilized a comprehensive approach to analyze gene expression patterns and regulatory networks in HCC. We integrated RNA sequencing data gathered from both tissue samples and exosomes. The WGCNA and limma R packages were employed to construct co-expression networks and identify differentially expressed ncRNAs, including long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs).

Results

Our analysis demonstrated distinct expression profiles of various ncRNAs in HCC, revealing their intricate interactions with cancer-related genes. Key findings include the identification of a network of microRNAs that interact with selected lncRNAs and their potential roles as biomarkers. Moreover, exosomal RNA was shown to effectively reflect tissue-specific gene expression changes.

Conclusions

The results of this study highlight the significance of exosomal ncRNAs in the progression of liver cancer, suggesting their potential as both diagnostic biomarkers and therapeutic targets. Future research should focus on the functional implications of these ncRNAs to further elucidate their roles in HCC and explore their applications in clinical settings.

肝细胞癌（HCC）是一个具有复杂分子基础的重大全球健康挑战。近年来，对非编码rna （ncRNAs）和外泌体在癌症生物学中的作用的理解取得了新的进展，为研究潜在的诊断和治疗策略开辟了新的途径。方法采用综合方法分析HCC的基因表达模式和调控网络。我们整合了从组织样本和外泌体收集的RNA测序数据。使用WGCNA和limma R包构建共表达网络并识别差异表达的ncRNAs，包括长链非编码rna （lncRNAs）和环状rna （circRNAs）。结果我们的分析显示了不同的ncrna在HCC中的不同表达谱，揭示了它们与癌症相关基因的复杂相互作用。主要发现包括鉴定与选定的lncrna相互作用的microrna网络及其作为生物标志物的潜在作用。此外，外泌体RNA被证明可以有效地反映组织特异性基因表达的变化。结论本研究结果强调了外泌体ncRNAs在肝癌进展中的重要意义，表明它们具有作为诊断生物标志物和治疗靶点的潜力。未来的研究应关注这些ncrna的功能意义，以进一步阐明它们在HCC中的作用，并探索它们在临床中的应用。

{"title":"Integrative analysis of exosomal ncRNAs and their regulatory networks in liver cancer progression","authors":"Farzin Mirzaei-nasab , Ahmad Majd , Yousef Seyedena , Nazanin Hosseinkhan , Najma Farahani , Mehrdad Hashemi","doi":"10.1016/j.plabm.2025.e00464","DOIUrl":"10.1016/j.plabm.2025.e00464","url":null,"abstract":"<div><h3>Background</h3><div>Hepatocellular carcinoma (HCC) is a significant global health challenge with complex molecular underpinnings. Recent advancements in understanding the role of non-coding RNAs (ncRNAs) and exosomes in cancer biology have opened new avenues for research into potential diagnostic and therapeutic strategies.</div></div><div><h3>Methods</h3><div>This study utilized a comprehensive approach to analyze gene expression patterns and regulatory networks in HCC. We integrated RNA sequencing data gathered from both tissue samples and exosomes. The WGCNA and limma R packages were employed to construct co-expression networks and identify differentially expressed ncRNAs, including long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs).</div></div><div><h3>Results</h3><div>Our analysis demonstrated distinct expression profiles of various ncRNAs in HCC, revealing their intricate interactions with cancer-related genes. Key findings include the identification of a network of microRNAs that interact with selected lncRNAs and their potential roles as biomarkers. Moreover, exosomal RNA was shown to effectively reflect tissue-specific gene expression changes.</div></div><div><h3>Conclusions</h3><div>The results of this study highlight the significance of exosomal ncRNAs in the progression of liver cancer, suggesting their potential as both diagnostic biomarkers and therapeutic targets. Future research should focus on the functional implications of these ncRNAs to further elucidate their roles in HCC and explore their applications in clinical settings.</div></div>","PeriodicalId":20421,"journal":{"name":"Practical Laboratory Medicine","volume":"45 ","pages":"Article e00464"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analytical performance evaluation of intelligent quality management of blood gas analyzer 血气分析仪智能质量管理分析性能评价

IF 1.7 Q3 MEDICAL LABORATORY TECHNOLOGY

Practical Laboratory Medicine

Pub Date : 2025-07-01 Epub Date: 2025-05-29 DOI: 10.1016/j.plabm.2025.e00480

Hongting Tang , Yawen Xiao , Hong Luo, Jian Jiang, Hanqing Xu, Jun Yang, Lihua Yang, Xiang Yang

Objective

This study aimed to compare the application effectiveness and quality control (QC) performance of intelligent quality management for blood gas analysis (BGA) with those of traditional quality management.

Methods

We implemented intelligent quality management by employing the GEM Premier 5000 equipped with Intelligent Quality Management 2 (iQM 2). By collecting external quality assessment (EQA) and internal quality control (IQC) data, we compared the clinical application outcomes and quality control (QC) performance between the intelligent management and traditional management approaches.

Results

The average bias of EQA for pH, partial carbon dioxide pressure (pCO₂), partial oxygen pressure (pO₂), sodium (Na⁺) and calcium (Ca²⁺) decreased compared to pre-management levels; except for pO₂, the average coefficient of variation (CV%) of intelligent QC was lower. The average estimated total error (TE) in the intelligent QC met the specified acceptance criterion. According to the average sigma and the goal index ratio (QGI), both QC modes have issues with accuracy and precision; the probabilities of false rejection (Pfr) of traditional QC and intelligent QC are almost the same; except for pO₂ and Na⁺, the probability of error detection (Ped) of intelligent QC is greater, whereas the average detection time (ADT) of traditional QC is greater. In addition, intelligent QC identified errors in approximately 1.46 % of the samples.

Conclusions

The precision and accuracy of the BGA improved significantly compared to those before management, indicating significant advantages of intelligent quality management in quality management applications.

目的比较血气分析（BGA）智能质量管理与传统质量管理的应用效果和质量控制性能。方法采用配备智能质量管理2 （iqm2）的GEM Premier 5000进行智能质量管理。通过收集外部质量评估（EQA）和内部质量控制（IQC）数据，比较智能管理与传统管理方法的临床应用效果和质量控制（QC）绩效。结果EQA对pH、二氧化碳分压（pCO2）、氧气分压（pO2）、钠（Na+）和钙（Ca2+）的平均偏差较管理前有所降低；除pO2外，智能QC的平均变异系数（CV%）均较低。智能QC的平均估计总误差（TE）满足规定的验收标准。从平均西格玛和目标指数比（QGI）来看，两种QC模式都存在准确性和精密度的问题；传统质量控制与智能质量控制的误拒概率基本一致；除了pO2和Na+外，智能QC的错误检测概率（Ped）更大，而传统QC的平均检测时间（ADT）更大。此外，智能QC在大约1.46%的样品中发现了错误。结论BGA的精密度和准确度较管理前有明显提高，说明智能质量管理在质量管理应用中的优势显著。

{"title":"Analytical performance evaluation of intelligent quality management of blood gas analyzer","authors":"Hongting Tang , Yawen Xiao , Hong Luo, Jian Jiang, Hanqing Xu, Jun Yang, Lihua Yang, Xiang Yang","doi":"10.1016/j.plabm.2025.e00480","DOIUrl":"10.1016/j.plabm.2025.e00480","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to compare the application effectiveness and quality control (QC) performance of intelligent quality management for blood gas analysis (BGA) with those of traditional quality management.</div></div><div><h3>Methods</h3><div>We implemented intelligent quality management by employing the GEM Premier 5000 equipped with Intelligent Quality Management 2 (iQM 2). By collecting external quality assessment (EQA) and internal quality control (IQC) data, we compared the clinical application outcomes and quality control (QC) performance between the intelligent management and traditional management approaches.</div></div><div><h3>Results</h3><div>The average bias of EQA for pH, partial carbon dioxide pressure (pCO<sub>2</sub>), partial oxygen pressure (pO<sub>2</sub>), sodium (Na<sup>+</sup>) and calcium (Ca<sup>2+</sup>) decreased compared to pre-management levels; except for pO<sub>2</sub>, the average coefficient of variation (CV%) of intelligent QC was lower. The average estimated total error (TE) in the intelligent QC met the specified acceptance criterion. According to the average sigma and the goal index ratio (QGI), both QC modes have issues with accuracy and precision; the probabilities of false rejection (Pfr) of traditional QC and intelligent QC are almost the same; except for pO<sub>2</sub> and Na<sup>+</sup>, the probability of error detection (Ped) of intelligent QC is greater, whereas the average detection time (ADT) of traditional QC is greater. In addition, intelligent QC identified errors in approximately 1.46 % of the samples.</div></div><div><h3>Conclusions</h3><div>The precision and accuracy of the BGA improved significantly compared to those before management, indicating significant advantages of intelligent quality management in quality management applications.</div></div>","PeriodicalId":20421,"journal":{"name":"Practical Laboratory Medicine","volume":"45 ","pages":"Article e00480"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0